On April 12, 2024, the "World Premiere of Saite (Epnermine for Injection) and the Release of Guidelines for the Clinical Application of Epnermine" was held in Beijing. As a demonstration of the achievements of the "Tenth Five-Year Plan" National Major Science and Technology Project (863 Program) and the "13th Five-Year Plan" National "Major New Drug Creation" Special Support Project, nearly 100 experts in the field of hematology and oncology were invited to witness this exciting moment.
The meeting kicked off with the speech of the presidium of the conference, Academician Huang Xiaojun of Peking University People's Hospital, Professor Shen Zhixiang of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Professor Wu Depei of the First Affiliated Hospital of Soochow University, Professor Hu Yu of Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Professor Ma Jun of Harbin Institute of Hematology and Oncology, Professor Zhu Jun of Peking University Cancer Hospital, Professor Hou Jian of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Professor Li Juan of the First Affiliated Hospital of Sun Yat-sen University, Professor Chen Wenming from Beijing Chaoyang Hospital affiliated to Capital Medical University expressed his respect for the exploration of domestic enterprises in the "no man's land" and his expectations for the clinical potential of the drug itself, and wished the conference a complete success on the successful launch of Shait, a class 1 drug independently developed by Chinese people with new targets.
Subsequently, Mr. Chen Ya, Chairman of Wuhan Haite Biopharmaceutical Co., Ltd. (hereinafter referred to as Haite Biopharmaceutical), delivered a welcome speech to the participating experts. Mr. Chen Ya said that as a "new product in the world and innovative in China", the advent of Shaite has provided a new choice and brought new hope to the treatment options for patients with multiple myeloma. The development and listing of Shaite is inseparable from the R&D team's spirit of overcoming difficulties and moving forward bravely, which is also the practice of the corporate tenet of "reverence for life and fearless innovation", and at the same time, it is also inseparable from the strong support of nearly 50 cooperative units and more than 60 PIs in the clinical trial of Shait, and Mr. Chen Ya also expressed his respect and gratitude to all researchers again through this meeting.
In the follow-up academic exchange session, Professor Chen Wenming and Professor Zhao Donglu of Harbin Institute of Hematology and Oncology respectively discussed "Review of Clinical Trial Data of Eppenamine" <埃普奈明临床应用指导原则>and " Interpretation" made keynote speeches. As the principal investigator of a number of pre-marketing clinical trials, Professor Chen Wenming systematically reviewed the results of the confirmatory clinical trial of Shayt: CPT-MM301 and made a comprehensive interpretation of the characteristics of Shaite in clinical trials. Based on the "Guidelines for the Clinical Application of Eppenamine in the Treatment of Relapsed and Refractory Multiple Myeloma" jointly issued by the Leukemia Expert Committee of the Chinese Society of Clinical Oncology (CSCO), the CSCO Lymphoma Expert Committee and the CSCO Myeloma Preparatory Committee, Professor Zhao Donglu gave suggestions on the selection of combined application regimens, drug ideas for special populations, and dose adjustment of Saite on issues of practical concern to clinical experts.
In the academic discussion session, nearly 40 experts in the field of hematology from all over the country exchanged views on the main challenges of clinical treatment of multiple myeloma at this stage, the advantages of Shaite in clinical trials, the application scenarios of new mechanism drugs in the clinical practice of multiple myeloma, the current treatment ideas of patients with multiple myeloma with aggressive recurrence, and the future exploration direction of Shaat's clinical application. At the same time, the panelists shared their experience in the treatment of high-risk patients with myeloma based on their professional background and the actual situation in their regions. Experts who have participated in the clinical trials of Saite discussed the future application direction of DR4/DR5 agonists with colleagues who have learned about Saite for the first time.
The summary session of the conference was jointly conducted by Professor Ma Jun, Professor Shen Zhixiang, Professor Shao Zonghong and Professor Hou Jian of Tianjin Medical University General Hospital, and several guests fully affirmed the positive significance of the exchange of experience in the diagnosis and treatment of multiple myeloma at this conference, and expressed their ardent expectations for the future clinical application of Shaite as a new tool for the treatment of multiple myeloma. Taking the results of this meeting as a starting point, Hite Biotech will actively lay out the application of Shaite in other hematological tumors and even solid tumors, so as to help more cancer patients regain the excitement of life.
审校:Eve排版:Eve执行:Eve
This platform aims to deliver more medical information to healthcare professionals. The content published on this platform should not be used as a substitute for professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice. If such information is used for purposes other than understanding medical information, the platform does not assume relevant responsibilities. This platform does not mean that it agrees with its descriptions and views on the published content. If copyright issues are involved, please contact us, and we will deal with it as soon as possible.